<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40887630</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.</ArticleTitle><Pagination><StartPage>351</StartPage><MedlinePgn>351</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">351</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-025-02912-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiovascular (CV) outcome trials have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce CV mortality in type 2 diabetes (T2DM). We previously found that 4&#xa0;weeks of SGLT2i treatment increased coronary flow reserve (CFR) by 30% and reduced epicardial adipose tissue (EAT) thickness by 19% in T2DM patients with stable coronary artery disease (CAD). However, long-term effects remain unclear. This pilot study aimed to assess the long-term impact of dapagliflozin on CFR and EAT thickness in T2DM patients with CAD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with T2DM and stable CAD were enrolled in the DAPAHEART trial, a single-center, 4-week, randomized (1:1 dapagliflozin 10&#xa0;mg vs. placebo), double-blind, controlled study. At the end of the trial, placebo group patients also transitioned to dapagliflozin. CFR and EAT thickness were measured at baseline, after 4&#xa0;weeks, and after 4&#xa0;years using <sup>13</sup>N-ammonia PET/CT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CFR increased 34.4% after 4&#xa0;years (from 2.15&#x2009;&#xb1;&#x2009;0.19 at baseline to 2.85&#x2009;&#xb1;&#x2009;0.26, p&#x2009;=&#x2009;0.001) with 29.18% reduction in EAT thickness (p&#x2009;=&#x2009;0.03). BMI decreased in all patients (p&#x2009;=&#x2009;0.001), but changes in BMI and EAT thickness were not significantly correlated (R<sup>2&#x2009;</sup>=&#x2009;0.0662; p&#x2009;=&#x2009;0.5), suggesting a weight-independent effect of dapagliflozin on EAT.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The 30% CFR improvement seen after 4&#xa0;weeks of dapagliflozin persisted at 4&#xa0;years, together with a significant reduction in EAT thickness, possibly explaining CFR improvement. Similar results in the placebo group after treatment strongly support a causal relationship and underscore the long-term CV benefits of dapagliflozin and its role in reducing CV risk in T2DM patients.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cinti</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy. cinti_francesca@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Morciano</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Guarneri</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cappannoli</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UOC di Cardiologia, Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sorice</LastName><ForeName>GianPio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sezione di Medicina Interna, Endocrinologia, Andrologia e Malattie Metaboliche, Dipartimento di Medicina di Precisione e Rigenerativa e Area Jonica - (DiMePRe-J), Universit&#xe0; degli Studi di Bari "Aldo Moro", Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gugliandolo</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capece</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Splendore</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avolio</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezza</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iozzo</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche (CNR), Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvi</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calcagni</LastName><ForeName>Maria Lucia</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sezione di Medicina Nucleare, Dipartimento di Scienze Radiologiche ed Ematologia, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burzotta</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>UOC di Cardiologia, Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amario</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>UOC di Cardiologia, Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Medicina Traslazionale, Azienda Ospedaliera Universitaria Maggiore della Carit&#xe0;, Diparimento toraco-cardio-vascolare, UOC Cardiologia 1, Universit&#xe0; del Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crea</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>UOC di Cardiologia, Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Leccisotti</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sezione di Medicina Nucleare, Dipartimento di Scienze Radiologiche ed Ematologia, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Giaccari</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy. andrea.giaccari@unicatt.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1ULL0QJ8UC</RegistryNumber><NameOfSubstance UI="C529054">dapagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="Y">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053805" MajorTopicYN="Y">Fractional Flow Reserve, Myocardial</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Coronary flow reserve</Keyword><Keyword MajorTopicYN="N">Dapagliflozin</Keyword><Keyword MajorTopicYN="N">Epicardial adipose tissue</Keyword><Keyword MajorTopicYN="N">Long-term coronary flow reserve</Keyword><Keyword MajorTopicYN="N">SGLT2i</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was approved by the local ethics committee (Fondazione Policlinico Universitario Agostino Gemelli IRCCS, study protocol code GIA-DAP-16&#x2013;005) and registered at eudract.ema.europa.eu (EudraCT No. 2016&#x2013;003614-27) and ClinicalTrials.gov (NCT 03313752). Written informed consent was obtained from all participants. Consent for publication: The corresponding author certifies the accuracy of content, in particular, the names of coauthors and that addresses and affiliations are up to date. The corresponding author certifies that all the co-authors have agreed to all the contents and will notify all the authors when the manuscript is accepted. The corresponding author certifies that all authors have seen and approved the final version of the paper, and all are aware of the submission of the paper. All authors consent to publication. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>4</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40887630</ArticleId><ArticleId IdType="pmc">PMC12400749</ArticleId><ArticleId IdType="doi">10.1186/s12933-025-02912-4</ArticleId><ArticleId IdType="pii">10.1186/s12933-025-02912-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Rosa S, et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2. 10.3389/fendo.2018.00002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776102</ArticleId><ArticleId IdType="pubmed">29387042</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008&#x2013;17. 10.1016/S0140-6736(14)60794-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24910232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahaffey KW, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018;137:323&#x2013;34. 10.1161/CIRCULATIONAHA.117.032038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777572</ArticleId><ArticleId IdType="pubmed">29133604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (sglt2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632&#x2013;44. 10.1016/j.jacbts.2020.02.004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315190</ArticleId><ArticleId IdType="pubmed">32613148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinti F, et al. The effects of SGLT2i on cardiac metabolism in patients with HFpEF: fact or fiction? Cardiovasc Diabetol. 2025;24:208. 10.1186/s12933-025-02767-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12079913</ArticleId><ArticleId IdType="pubmed">40369599</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amario D, et al. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2024;11:2063&#x2013;75. 10.1002/ehf2.14626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11287310</ArticleId><ArticleId IdType="pubmed">38549197</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31&#x2013;9. 10.1016/S0140-6736(18)32590-X.</Citation><ArticleIdList><ArticleId IdType="pubmed">30424892</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen AJ. EMPA-REG OUTCOME: empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk. Rev Med Liege. 2015;70:583&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26738271</ArticleId></ArticleIdList></Reference><Reference><Citation>Beernink JM, et al. Efficacy of Dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care. 2023;46:602&#x2013;7. 10.2337/dc22-1514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10020024</ArticleId><ArticleId IdType="pubmed">36662635</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewiara L, et al. Impaired coronary flow reserve in patients with poor type 2 diabetes control: preliminary results from prospective microvascular dysfunction registry. Cardiol J. 2024;31:185&#x2013;92. 10.5603/CJ.a2022.0100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11076028</ArticleId><ArticleId IdType="pubmed">36342032</ArticleId></ArticleIdList></Reference><Reference><Citation>Galante D, et al. Fractional flow reserve (FFR) and index of microcirculatory resistance (IMR) relationship in patients with chronic or stabilized acute coronary syndromes. Int J Cardiol. 2025;422:132978. 10.1016/j.ijcard.2025.132978.</Citation><ArticleIdList><ArticleId IdType="pubmed">39800227</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitenberg A, et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993;42:1017&#x2013;25. 10.2337/diab.42.7.1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitenberg A, et al. Impairment of coronary microvascular dilation in response to cold pressor&#x2013;induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes. 2001;50:1180&#x2013;5. 10.2337/diabetes.50.5.1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">11334424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, et al. Coronary flow reserve by cardiac magnetic resonance imaging in patients with diabetes mellitus. JACC Cardiovasc Imaging. 2019;12:2579&#x2013;80. 10.1016/j.jcmg.2019.07.010.</Citation><ArticleIdList><ArticleId IdType="pubmed">31542531</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesti L, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol. 2022;21:181. 10.1186/s12933-022-01618-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467417</ArticleId><ArticleId IdType="pubmed">36096863</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593&#x2013;606. 10.1038/s41569-022-00679-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926097</ArticleId><ArticleId IdType="pubmed">35296869</ArticleId></ArticleIdList></Reference><Reference><Citation>Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101&#x2013;11. 10.1093/eurheartj/eht513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006091</ArticleId><ArticleId IdType="pubmed">24366916</ArticleId></ArticleIdList></Reference><Reference><Citation>Malavazos AE, et al. The density of crown-like structures in epicardial adipose tissue could play a role in cardiovascular diseases. Eat Weight Disord. 2022;27:2905&#x2013;10. 10.1007/s40519-022-01420-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35678980</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano A, et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res. 2013;54:2423&#x2013;36. 10.1194/jlr.M038638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735940</ArticleId><ArticleId IdType="pubmed">23836106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzbeck P, et al. Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. J Lipid Res. 2018;59:784&#x2013;94. 10.1194/jlr.M079665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928436</ArticleId><ArticleId IdType="pubmed">29599420</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano A, et al. The adipose organ is a unitary structure in mice and humans. Biomedicines. 2022;10(9):2275. 10.3390/biomedicines10092275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9496043</ArticleId><ArticleId IdType="pubmed">36140375</ArticleId></ArticleIdList></Reference><Reference><Citation>Recio-Mayoral A, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009;30:1837&#x2013;43. 10.1093/eurheartj/ehp205.</Citation><ArticleIdList><ArticleId IdType="pubmed">19502228</ArticleId></ArticleIdList></Reference><Reference><Citation>Taqueti VR, Ridker PM. Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. JACC Cardiovasc Imaging. 2013;6:668&#x2013;71. 10.1016/j.jcmg.2013.02.005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962806</ArticleId><ArticleId IdType="pubmed">23764095</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobellis G, Baroni MG. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest. 2022;45:489&#x2013;95. 10.1007/s40618-021-01687-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">34643917</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedicino D, et al. Epicardial adipose tissue microbial colonization and inflammasome activation in acute coronary syndrome. Int J Cardiol. 2017;236:95&#x2013;9. 10.1016/j.ijcard.2017.02.040.</Citation><ArticleIdList><ArticleId IdType="pubmed">28268083</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniades C, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J. 2023. 10.1093/eurheartj/ehad484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10568001</ArticleId><ArticleId IdType="pubmed">37599464</ArticleId></ArticleIdList></Reference><Reference><Citation>Succurro E, et al. Impaired insulin-stimulated myocardial glucose metabolic rate is associated with reduced estimated myocardial energetic efficiency in subjects with different degrees of glucose tolerance. Cardiovasc Diabetol. 2023;22:4. 10.1186/s12933-022-01733-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9827706</ArticleId><ArticleId IdType="pubmed">36624469</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanessa Fiorentino T, et al. Depressed myocardial mechano-energetic efficiency in subjects with dysglycemia. Diabetes Res Clin Pract. 2021;177:108883. 10.1016/j.diabres.2021.108883.</Citation><ArticleIdList><ArticleId IdType="pubmed">34082055</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancusi C, et al. Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network. J Hum Hypertens. 2017;31:424. 10.1038/jhh.2017.3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28465617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorice GP, et al. Effect of dapagliflozin on myocardial insulin sensitivity and perfusion: rationale and design of the DAPAHEART trial. Diabetes Ther. 2021;12:2101&#x2013;13. 10.1007/s13300-021-01083-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8266960</ArticleId><ArticleId IdType="pubmed">34037951</ArticleId></ArticleIdList></Reference><Reference><Citation>Leccisotti L, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173. 10.1186/s12933-022-01607-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9440459</ArticleId><ArticleId IdType="pubmed">36057768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinti F, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:349. 10.1186/s12933-023-02091-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10731727</ArticleId><ArticleId IdType="pubmed">38115004</ArticleId></ArticleIdList></Reference><Reference><Citation>Uren NG, et al. Delayed recovery of coronary resistive vessel function after coronary angioplasty. J Am Coll Cardiol. 1993;21:612&#x2013;21. 10.1016/0735-1097(93)90092-f.</Citation><ArticleIdList><ArticleId IdType="pubmed">8436742</ArticleId></ArticleIdList></Reference><Reference><Citation>Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503&#x2013;16. 10.1056/NEJMoa070829.</Citation><ArticleIdList><ArticleId IdType="pubmed">17387127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciagra R, et al. EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2021;48:1040&#x2013;69. 10.1007/s00259-020-05046-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603916</ArticleId><ArticleId IdType="pubmed">33135093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu C, et al. Effects of sodium-glucose transporter 2 inhibitors (sglt2-i) in patients with ischemic heart disease (ihd) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up. Front Pharmacol. 2021;12:777083. 10.3389/fphar.2021.777083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634684</ArticleId><ArticleId IdType="pubmed">34867407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab. 2012;303:E937&#x2013;49. 10.1152/ajpendo.00061.2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22895783</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte M, et al. Inflammation and cardiovascular diseases in the elderly: the role of epicardial adipose tissue. Front Med (Lausanne). 2022;9:844266. 10.3389/fmed.2022.844266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8887867</ArticleId><ArticleId IdType="pubmed">35242789</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyuler S, Turker Duyuler P. Epicardial adipose tissue in coronary microvascular dysfunction. Int J Obes (Lond). 2022;46:1564. 10.1038/s41366-022-01125-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035972</ArticleId><ArticleId IdType="pubmed">35468930</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med. 2005;2:536&#x2013;43. 10.1038/ncpcardio0319.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186852</ArticleId></ArticleIdList></Reference><Reference><Citation>Spallone V, Valensi P. SGLT2 inhibitors and the autonomic nervous system in diabetes: a promising challenge to better understand multiple target improvement. Diabetes Metab. 2021;47:101224. 10.1016/j.diabet.2021.101224.</Citation><ArticleIdList><ArticleId IdType="pubmed">33454436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomidis I, et al. Insulin resistance and acute glucose changes determine arterial elastic properties and coronary flow reserve in dysglycaemic and first-degree relatives of diabetic patients. Atherosclerosis. 2015;241:455&#x2013;62. 10.1016/j.atherosclerosis.2015.06.006.</Citation><ArticleIdList><ArticleId IdType="pubmed">26081121</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto K, et al. Acute hyperglycemia induced by oral glucose loading suppresses coronary microcirculation on transthoracic Doppler echocardiography in healthy young adults. Echocardiography. 2006;23:829&#x2013;34. 10.1111/j.1540-8175.2006.00325.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">17069600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancusi C, et al. Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network. J Hum Hypertens. 2017;31:395&#x2013;9. 10.1038/jhh.2016.88.</Citation><ArticleIdList><ArticleId IdType="pubmed">28032631</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancusi C, et al. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort. Cardiovasc Diabetol. 2019;18:56. 10.1186/s12933-019-0862-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492323</ArticleId><ArticleId IdType="pubmed">31039789</ArticleId></ArticleIdList></Reference><Reference><Citation>Admani B, Fahim M, Ahmed H. Semaglutide and weight loss: a concern for diabetics and pharmaceuticals. J Pak Med Assoc. 2024;74:1204. 10.47391/JPMA.10705.</Citation><ArticleIdList><ArticleId IdType="pubmed">38949006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzoulis P, Batavanis M, Baldeweg S. A real-world study of the effectiveness and safety of semaglutide for weight loss. Cureus. 2024;16:e59558. 10.7759/cureus.59558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11144277</ArticleId><ArticleId IdType="pubmed">38826889</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift C, et al. Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide. Diabetes Obes Metab. 2024;26:2111&#x2013;8. 10.1111/dom.15516.</Citation><ArticleIdList><ArticleId IdType="pubmed">38418411</ArticleId></ArticleIdList></Reference><Reference><Citation>Malavazos AE, et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Eur J Prev Cardiol. 2023;30:680&#x2013;93. 10.1093/eurjpc/zwad050.</Citation><ArticleIdList><ArticleId IdType="pubmed">36799940</ArticleId></ArticleIdList></Reference><Reference><Citation>Morciano C, et al. SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives. Cardiovasc Diabetol. 2024;23:449. 10.1186/s12933-024-02539-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11660748</ArticleId><ArticleId IdType="pubmed">39702365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>